New reporting on biotech and med-tech capital markets highlights improving fundraising conditions alongside a wave of larger transactions. One dataset review found early 2026 showed strong series A sizing even as deal counts remained lower, with median Series A size rising and investment concentrated among companies with clinical differentiation and commercialization paths. Separately, broader M&A commentary tied to first-half 2026 deal value pointed to a record-breaking pace in biopharma acquisitions, with June contributing significant share of total first-half haul. Financing activity and dealmaking together are being framed as indicators that sentiment is stabilizing. Venture commentary suggested funding is increasingly “selective,” with capital flowing to management teams and programs able to de-risk outcomes and show clear market pathways. Taken together, these items suggest that capital availability in biotech is improving but not uniform, with investors continuing to demand stronger evidence packages as they reposition for higher conviction entries.